Emerald Advisers’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $193K | Hold |
20,768
| – | – | 0.01% | 220 |
|
|
2025
Q1 | $152K | Hold |
20,768
| – | – | 0.01% | 216 |
|
|
2024
Q4 | $177K | Hold |
20,768
| – | – | 0.01% | 221 |
|
|
2024
Q3 | $181K | Hold |
20,768
| – | – | 0.01% | 218 |
|
|
2024
Q2 | $142K | Hold |
20,768
| – | – | 0.01% | 224 |
|
|
2024
Q1 | $189K | Hold |
20,768
| – | – | 0.01% | 224 |
|
|
2023
Q4 | $92.6K | Hold |
20,768
| – | – | ﹤0.01% | 225 |
|
|
2023
Q3 | $65.2K | Sell |
20,768
-24,949
| -55% | -$78.3K | ﹤0.01% | 215 |
|
|
2023
Q2 | $236K | Hold |
45,717
| – | – | 0.01% | 205 |
|
|
2023
Q1 | $241K | Sell |
45,717
-919,524
| -95% | -$4.85M | 0.01% | 203 |
|
|
2022
Q4 | $2.71M | Sell |
965,241
-541,215
| -36% | -$1.52M | 0.13% | 113 |
|
|
2022
Q3 | $6.25M | Buy |
1,506,456
+40,754
| +3% | +$169K | 0.32% | 101 |
|
|
2022
Q2 | $5.89M | Buy |
1,465,702
+173,797
| +13% | +$699K | 0.3% | 103 |
|
|
2022
Q1 | $6.4M | Buy |
1,291,905
+234,178
| +22% | +$1.16M | 0.24% | 109 |
|
|
2021
Q4 | $7.37M | Buy |
1,057,727
+208,127
| +24% | +$1.45M | 0.27% | 108 |
|
|
2021
Q3 | $8.5M | Sell |
849,600
-373,900
| -31% | -$3.74M | 0.31% | 104 |
|
|
2021
Q2 | $17.3M | Sell |
1,223,500
-71,350
| -6% | -$1.01M | 0.63% | 72 |
|
|
2021
Q1 | $21.2M | Buy |
1,294,850
+104,147
| +9% | +$1.71M | 0.77% | 53 |
|
|
2020
Q4 | $24.6M | Buy |
+1,190,703
| New | +$24.6M | 0.82% | 48 |
|